Not Yet RecruitingPhase 2

Modified Conditioning Regimen for CML-BP

40 participantsStarted 2025-12-15

Plain-language summary

Study on the Efficacy and Safety of a Reduced-Toxicity Conditioning Regimen Containing Thiotepa and Melphalan in Patients with Blast Phase Chronic Myeloid Leukemia

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Peripheral blood or bone marrow blasts ≥20%
✓. Aggregates of blasts on bone marrow biopsy
✓. Extramedullary blast cell infiltration (2) Age ≥18 years (3) Ability to provide self-signed informed consent (4) Must meet adequate organ function requirements:

What they're measuring

overall survival, OS

Timeframe: 2 year

Trial details

NCT IDNCT07259161

SponsorInstitute of Hematology & Blood Diseases Hospital, China

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2029-09-14

Contact for this trial

Erlie Jiang

022-23608569 jiangerlie@ihcams.ac.cn

View on ClinicalTrials.gov More CML,Blast Phase trials